Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT06253871

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Led by Iambic Therapeutics, Inc · Updated on 2026-04-13

383

Participants Needed

48

Research Sites

244 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

CONDITIONS

Official Title

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 65 18 years
  • Have relapsed or refractory HER2-altered cancer
  • For selected groups, confirmation of HER2 alteration through central testing is required
  • Disease progression after last systemic therapy or intolerance to last therapy
  • Measurable disease by imaging using RECIST v1.1 and/or RANO-BM criteria
  • Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1
  • Adequate blood, liver, and kidney function at baseline
  • Left ventricular ejection fraction (LVEF) 65 50%
  • Able to swallow oral medication
Not Eligible

You will not qualify if you...

  • Clinically significant heart disease
  • Infection with HIV-1 or HIV-2 unless well controlled (CD4 >350/mm3 and undetectable viral load)
  • Active liver disease including hepatitis A, B, or C
  • Severe nausea, vomiting, malabsorption, external biliary shunt, or major small bowel surgery preventing proper absorption
  • Uncontrolled diabetes
  • History of solid organ transplant
  • History of grade 2 or higher central nervous system hemorrhage or any CNS hemorrhage within 28 days before starting treatment
  • Prior non-infectious interstitial lung disease except completely resolved grade 1 cases
  • Need for immediate local treatment for brain metastases

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 48 locations

1

UCSD Moores Cancer Center

La Jolla, California, United States, 92093

Actively Recruiting

2

USC Norris Comprehensive Cancer Center

Los Angeles, California, United States, 90089

Actively Recruiting

3

University of Colorado Cancer Center

Aurora, Colorado, United States, 80045

Actively Recruiting

4

University of Miami

Miami, Florida, United States, 33136

Actively Recruiting

5

Comprehensive Hematology Oncology

St. Petersburg, Florida, United States, 33709

Actively Recruiting

6

University of Chicago

Chicago, Illinois, United States, 60637

Actively Recruiting

7

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

8

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Actively Recruiting

9

University of Michigan

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

10

Henry Ford Cancer Institute

Detroit, Michigan, United States, 48202

Actively Recruiting

11

START - Midwest Cancer Research Center

Grand Rapids, Michigan, United States, 49546

Actively Recruiting

12

Saint Luke's Cancer Institute

Kansas City, Missouri, United States, 64111

Actively Recruiting

13

Washington University School of Medicine

St Louis, Missouri, United States, 63110

Actively Recruiting

14

RUTGERS Cancer Institute

New Brunswick, New Jersey, United States, 08901

Actively Recruiting

15

Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10029

Actively Recruiting

16

Duke Cancer Institute

Durham, North Carolina, United States, 27710

Actively Recruiting

17

University Hospital Cleveland Medical Center

Cleveland, Ohio, United States, 44106

Actively Recruiting

18

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Actively Recruiting

19

OU Health Stephenson Cancer Center

Oklahoma City, Oklahoma, United States, 73104

Actively Recruiting

20

Providence Cancer Institute

Portland, Oregon, United States, 97213

Actively Recruiting

21

SCRI Oncology Partners

Nashville, Tennessee, United States, 37203

Actively Recruiting

22

Vanderbilt Ingram Cancer Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

23

NEXT Oncology - Austin

Austin, Texas, United States, 78758

Actively Recruiting

24

NEXT Oncology - Dallas

Dallas, Texas, United States, 75039

Actively Recruiting

25

Mary Crowley Cancer Research

Dallas, Texas, United States, 75230

Actively Recruiting

26

MD Anderson Cancer Center - University of Texas

Houston, Texas, United States, 77030

Actively Recruiting

27

START Mountain Region

West Valley City, Utah, United States, 84119

Actively Recruiting

28

NEXT Oncology - Virginia Cancer Specialists

Fairfax, Virginia, United States, 22031

Actively Recruiting

29

Fred Hutchinson Cancer Center

Seattle, Washington, United States, 98109

Actively Recruiting

30

Centre Georges François Leclerc

Dijon, France, 21079

Actively Recruiting

31

Institut de Cancerologie de l'Ouest

Saint-Herblain, France, 44805

Actively Recruiting

32

Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole Institut Claudius Regaud "

Toulouse, France, 31059

Actively Recruiting

33

The START center Dublin

Dublin, Dublin, Ireland, D07 R2WY

Actively Recruiting

34

Cork University Hospital, Wilton

Cork, Ireland, T12DC4A

Actively Recruiting

35

St. Vincent's University Hospital

Dublin, Ireland, D04 T6F4

Actively Recruiting

36

Azienda Ospedaliero Universitaria Careggi - Largo Giovanni Alessandro Brambilla 3

Florence, Italy, 50134

Actively Recruiting

37

Istituto Europeo di Oncologia (IEO)

Milan, Italy, 20141

Actively Recruiting

38

Netherlands Cancer Institute-Antoni van Leeuwenhoek

Amsterdam, Netherlands, 1066CX

Actively Recruiting

39

Seoul National University Hospital

Seoul, South Korea, 03080

Actively Recruiting

40

Severance Hospital - Yonsei Cancer Center

Seoul, South Korea, 03722

Actively Recruiting

41

Asan Medical Center

Seoul, South Korea, 05505

Actively Recruiting

42

Samsung Medical Center

Seoul, South Korea, 06351

Actively Recruiting

43

Hospital Universitario Vall dHebron

Barcelona, Spain, 08035

Actively Recruiting

44

Hospital Universitario 12 de Octubre

Madrid, Spain, 28041

Actively Recruiting

45

START Madrid CIOCC, Hospital Universitario HM Sanchinarro

Madrid, Spain, 28050

Actively Recruiting

46

Hospital Universitario Virgen del Rocio

Seville, Spain, 41013

Actively Recruiting

47

Hospital Clinico Universitario de Valencia (INCLIVA)

Valencia, Spain, 46010

Actively Recruiting

48

Oxford University Hospitals NHS Foundation Trust Churchill Hospital

Oxford, United Kingdom, OX3 7LE

Actively Recruiting

Loading map...

Research Team

I

Iambic Therapeutics, Inc., Senior Medical Director

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Phase 1/1b Study of IAM1363 in HER2 Cancers | DecenTrialz